Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LivaNova PLC - Ordinary Shares (NQ:LIVN)

62.53 +0.47 (+0.76%)
Streaming Delayed Price Updated: 3:15 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LivaNova PLC - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at J.P. Morgan Healthcare Conference in January
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Piper Sandler Healthcare Conference in December
From LivaNova PLC
Via Business Wire
News headline image
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Wolfe Research Healthcare Conference in November
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Third-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Donald Zurbay as a New Director
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Host Investor Day on November 12, 2025
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Launches Essenz Perfusion System in China
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Second-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at the Jefferies Global Healthcare Conference
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce First-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at the Barclays Global Healthcare Conference
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
From LivaNova PLC
Via Business Wire
News headline image
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.